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Adverse effects of drugs that are only identified after a
compound enters the clinic seriously limit therapeutic
potential and could result in withdrawal from the market.
Two well-known examples in recent years were Rofecoxib
(Vioxx®) and Cerivastatin (Baycol®, Lipobay®), but there
are many other examples. Avoiding such adverse effects is
therefore a key goal in drug discovery.
It is desirable to have a computational tool that predicts
possible problems even before a compound has been syn-
thesized. Bender et al. have shown a proof-of-principle for
predicting adverse events based on chemical structure [1].
In the current study we present an advancement of this
method. Approximately 200 marketed drugs were tested
against 80 different targets in the Novartis Safety Profiling
Panel and the IC50 values were determined. The well-doc-
umented adverse effects of these marketed drugs were
stored in a database using standard MedDRA terminol-
ogy.
For every side effect described by the MedDRA terminol-
ogy and every target covered by the Safety Profiling Panel
models were calculated and validated using both a Naïve
Bayesian classifier and Linear Discriminant Analysis in
conjunction with two chemical descriptors (Extended
Connectivity Fingerprints and MDL Public Keys). We
present results demonstrating correlations between chem-
ical features and adverse effects on the one hand, and
between targets and adverse effects on the other. Therefore
the method can be used for predicting adverse events
based on chemical structure alone. Furthermore, novel
links between targets and adverse effects can be unraveled
which are of interest in their own right, but which can also
be applied to select targets for in vitro compound profil-
ing.
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